PreOmics is a company that develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry.
PreOmics develops and provides innovative tools for customers around the world for mass spectrometry (MS)-based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry. They at PreOmics develop and provide innovative technologies for mass spectrometry-based proteomics to make your research simply better. Their mission is to provide you with the best possible solutions and at the highest quality to achieve your results faster, easier and in a more robust manner than ever before.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 19, 2022 | Series B | €13.50M | — | — | — | Detail |
Jan 1, 2019 | Grant | €71.42K | 1 | — | — | Detail |
Dec 27, 2018 | Series A | €3.30M | 3 | Think.Health | — | Detail |
Dec 27, 2018 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Think.Health | Yes | Series A |
EASME - EU Executive Agency for SMEs | — | Grant |
business angels | — | Series A |
High-Tech Grunderfonds | — | Series A |
TBA Tyrolean Business Angel | — | Series A |